Promising Novel ‘Smart Bomb’ Treatment for Pancreatic Cancer
The infinitesimal particles that could transport drugs and target cancerous growth could be the next major ray of hope in the treatment of those ailing from pancreatic cancer.
The novel research would be made public during the yearly convene of AAPS or American Association of Pharmaceutical Scientists, in November, in LA. The research shows how TPM or tumor-penetrating particles have been particularly intended to rupture through stubborn blockades and distribute drugs with greater efficacy as compared to the benchmark form of chemotherapy like those that are intravenously administered.
The initiator of the study, an AAPS fellow and a notable university professor from Ohio State University, Jessie L.S. Au, Pharm.D., Ph.D, explicates how the TPM are intended for treating cancer found in the peritoneal cavity. The peritoneal cavity comprises of organs inclusive of the pancreas, that are believed to harbour above 2,50,000 newly evolving cancer cases annually in just the United States. The Pancreatic tumor cells are enclosed by specialized cells that safeguard them from the effects of chemotherapy. Dr. Au further added that their objective was for employing TPM to penetrate this barricade and effectually convey drugs to the tumor cells – that is presently the leading hitch that a physician is faced with during treatment of pancreatic cancer.
The American Cancer Society reveals that pancreatic cancer is the fourth principal cause of cancer in the United States and above eighty percent of the thirty-eight thousand patients that are develop the disease face fatality in a year’s time following detection.
Dr. Au also the co-initiator of Optimum Therapeutics LLC, the company that is carrying forward TPM to clinical trials, expounds the manner in which TPM lets loose what the researchers dub as the ‘smart bomb’ of drugs for creating punctures in the tumors to facilitate easier reach of the TPM to the tumor cells. As soon as the TPM reaches within a tumor, it gradually discharges drug levels that are effectual for a span for many weeks, during which time they target both the swift and sluggish-spreading tumors. As the TPM was intended to freely move around and get to the tumors without getting brushed away by the lymphatic system, they are capable of staying for extended periods of times in the peritoneal cavity and distribute higher concentration drug dosages to the cancer-inflicted organ. It is this two-pronged drug attack strategy that is distinctive to the pancreatic cancer treatment.
With merely a single drug dose of TPM that proves to be similarly effectual as the several chemotherapy injections, TPM is known to deliver lesser degree of toxicity among patients that makes it an increasingly safe choice as compared to the standard course of treatments presently available.
Ze Lu, Ph.D., principal scientist cum project leader stated that on the basis of the heartening outcome in mice that conveyed embeds of human pancreatic cancer, they have been guardedly sanguine that TPM might offer advantages to patients ailing from this disease. He further mentioned that TPM could prove particularly beneficial for those patients in the final stages of the disease.
Dr. Lu stated that the researchers had been putting their unswerving efforts while working on TPM for over a decade and are hopeful of garnering the FDA nod for testing TPM on patients in 2010.
The researchers are working together with the physicians at the Medical University of South California that deem a potent usability of TPM, that alongside treatment of peritoneal metastases would also help in down staging or downsizing the tumors to make them serviceable.
